4.7 Article

B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19

Journal

EBIOMEDICINE
Volume 70, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ebiom.2021.103539

Keywords

Vaccination; Covid-19; SARS-CoV-2; T cell immunity; Pre-existing immunity; Humoral response

Funding

  1. Christian Doppler Research Association
  2. Medical University Linz

Ask authors/readers for more resources

The study found that prior COVID-19 infection enhanced immune responses after vaccination, especially in the B and T cell compartments. Individuals with prior infection produced high antibody concentrations and more efficient virus neutralization after vaccination, with stronger T cell responses.
Background: In recent months numerous health care professional acquired COVID-19 at the workplace resulting in significant shortages in medical and nursing staff. We investigated how prior COVID-19 affects SARSCoV-2 vaccination and how such knowledge could facilitate frugal vaccination strategies. Methods: In a cohort of 41 healthcare professionals with (n=14) and without (n=27) previous SARS-CoV-2 infection, we assessed the immune status before, during and after vaccination with BNT162b2. The humoral immune response was assessed by receptor binding domain ELISA and different SARS-CoV-2 neutralisation assays using wildtype and pseudo-typed viruses. T cell immunity against SARS-CoV-2 surface and nucleocapsid peptides were studied using interferon-gamma release assays and intracellular flow cytometry. Vaccine-related side effects were captured. Findings: Prior COVID-19 resulted in improved vaccine responses both in the B and T cell compartment. In vaccine recipients with prior COVID-19, the first vaccine dose induced high antibody concentrations comparable to seronegative vaccine recipients after two injections. This translated into more efficient neutralisation of virus particles, even more pronounced than expected from the RBD ELISA results. Furthermore, T cell responses were stronger in convalescents and particularly strong against the SARS-CoV-2 nucleocapsid protein. Interpretation: Herein, we corroborate recent findings suggesting that in convalescents a single vaccine dose is sufficient to boost adequate in vitro neutralisation of SARS-CoV-2 and therefore may be sufficient to induce adequate protection against severe COVID-19. New spike mutated virus variants render the highly conserved nucleocapsid protein - eliciting strong SARS-CoV-2 specific T cell immunity - an interesting additional vaccine target. (C) 2021 The Authors. Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Virology

Persistence of humoral response upon SARS-CoV-2 infection

Andrea Knies, Dennis Ladage, Ralf J. Braun, Janine Kimpel, Miriam Schneider

Summary: This study summarizes findings on the persistence of humoral response post SARS-CoV-2 infection, with IgG antibodies showing the longest duration of six to eight months, while IgM and IgA studies yielded mixed results. Most studies observed neutralizing antibodies lasting up to eight months, which have been associated with protection from re-infection.

REVIEWS IN MEDICAL VIROLOGY (2022)

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

Annika Roessler, Lydia Riepler, David Bante, Dorothee von Laer, Janine Kimpel

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Immunology

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

Michael Karbiener, Maria R. Farcet, Andreas Zollner, Taisei Masuda, Mitsuhiro Mori, Alexander R. Moschen, Thomas R. Kreil

Summary: This study directly compares the SARS-CoV-2 neutralizing antibody response elicited by three COVID-19 vaccines (protein-based, mRNA-based, and vector-based) and further supports the use of neutralizing antibody levels as a correlate of protection.

NPJ VACCINES (2022)

Article Gastroenterology & Hepatology

Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases

Andreas Zollner, Robert Koch, Almina Jukic, Alexandra Pfister, Moritz Meyer, Annika Roessler, Janine Kimpel, Timon E. Adolph, Herbert Tilg

Summary: The study investigates whether the persistence of SARS-CoV-2 antigen in infected tissues is responsible for postacute COVID-19 syndrome. The results suggest that viral antigen persistence may be the underlying cause of postacute COVID-19 and this concept should be validated in controlled clinical trials.

GASTROENTEROLOGY (2022)

Letter Medicine, General & Internal

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection

Annika Roessler, Ludwig Knabl, Dorothee von Laer, Janine Kimpel

Summary: Although some antibodies generated in persons recovering from infection with the omicron variant show cross-reactivity, a group of unvaccinated individuals were found to have largely ineffective antibodies against other viral strains.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Immunology

N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro

Michaela Lackner, Annika Roessler, Andre Volland, Marlena Nastassja Stadtmueller, Brigitte Muellauer, Zoltan Banki, Johannes Stroehle, Angela Luttick, Jennifer Fenner, Bettina Sarg, Leopold Kremser, Paul Tone, Heribert Stoiber, Dorothee von Laer, Thorsten Wolff, Carsten Schwarz, Markus Nagl

Summary: This study demonstrates the broad antiviral activity of N-chlorotaurine (NCT) against various viruses causing acute respiratory tract infections, including SARS-CoV-2, influenza viruses, and RSV. NCT exerts virucidal effects by chlorinating and oxidizing viral proteins, with enhanced activity in the presence of proteinaceous material. The findings suggest that the application of 1.0% NCT could be a comprehensive clinical strategy for the prevention and treatment of acute viral respiratory tract infections.

EMERGING MICROBES & INFECTIONS (2022)

Letter Medical Laboratory Technology

Increased PD-L1 surface expression on peripheral blood granulocytes and monocytes after vaccination with SARS-CoV2 mRNA or vector vaccine

Lorin Loacker, Janine Kimpel, Zoltan Banki, Christoph Q. Schmidt, Andrea Griesmacher, Markus Anliker

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Article Virology

High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz

Teresa Harthaller, Wegene Borena, David Bante, Helena Schafer, Oliver Strallhofer, Thomas Zoeggeler, Eva Hochmuth, Luiza Hoch, Annika Roessler, Dorothee von Laer, Janine Kimpel, Barbara Falkensammer

Summary: This study aimed to determine the seroprevalence of SARS-CoV-2 among the pediatric population in the district of Schwaz, Austria. The findings revealed that the age-standardized seroprevalence of previously unknown SARS-CoV-2 infection among the general pediatric population was 27%, and the true overall prevalence was 32.8%, significantly higher than the officially documented cases of 8.0%. This suggests a high extent of silent infections and potentially silent transmission in the pediatric population.

VIRUSES-BASEL (2022)

Article Public, Environmental & Occupational Health

Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak

Peter Willeit, Janine Kimpel, Hannes Winner, Teresa Harthaller, Helena Schafer, David Bante, Barbara Falkensammer, Annika Rossler, Lydia Riepler, Cornelia Ower, Magdalena Sacher, Dorothee von Laer, Wegene Borena

Summary: The aim of this study was to determine the seroprevalence of SARS-CoV-2 among the adult population in the district of Schwaz at the time of the implementation of a rapid mass vaccination campaign. The study found that the proportion of undocumented infections was 55.8% and estimated that at least two-thirds of the adult population were susceptible to the virus when the vaccination campaign started.

FRONTIERS IN PUBLIC HEALTH (2022)

Letter Infectious Diseases

Reduced sensitivity of antibody tests after omicron infection

Annika Roessler, Ludwig Knabl, Lisa-Maria Raschbichler, Evelyn Peer, Dorothee von Laer, Wegene Borena, Janine Kimpel

LANCET MICROBE (2023)

Article Multidisciplinary Sciences

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Annika Roessler, Antonia Netzl, Ludwig Knabl, Helena Schaefer, Samuel H. Wilks, David Bante, Barbara Falkensammer, Wegene Borena, Dorothee von Laer, Derek J. Smith, Janine Kimpel

Summary: Studies have shown that the omicron variant of SARS-CoV-2 is an immune escape variant. However, the BA.2 and BA.5 sub-variants of omicron have become dominant in many countries and replaced the BA.1 variant. Our analysis focused on whether BA.2 and BA.5 show further immune escape compared to BA.1. We found that unvaccinated individuals after a single exposure to BA.2 had limited cross-neutralizing antibodies to pre-omicron variants and BA.1.

NATURE COMMUNICATIONS (2022)

Article Immunology

miR-142 favors naive B cell residence in peripheral lymph nodes

Magdalena Hagen, Tirtha Chakraborty, William J. Olson, Martin Heitz, Natascha Hermann-Kleiter, Janine Kimpel, Brigitte Jenewein, Johanna Pertoll, Verena Labi, Klaus Rajewsky, Emmanuel Derudder

Summary: B lymphocyte development is a well-ordered process that leads to the formation of mature B cells capable of recognizing a variety of antigens. miRNA regulation plays a crucial role in B cell biology, especially in development and migration.

FRONTIERS IN IMMUNOLOGY (2022)

Article Infectious Diseases

Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial

Lisa Seekircher, Zoltan Banki, Janine Kimpel, Annika Roessler, Helena Schaefer, Barbara Falkensammer, David Bante, Lukas Forer, Sebastian Schonherr, Teresa Harthaller, Magdalena Sacher, Cornelia Ower, Lena Tschiderer, Hanno Ulmer, Florian Krammer, Dorothee von Laer, Wegene Borena, Peter Willeit

Summary: This study investigated the associations between antibody and T-cell responses after COVID-19 vaccination and the risk of SARS-CoV-2 breakthrough infection, as well as whether measurement of these responses enhances risk prediction.

LANCET MICROBE (2023)

Article Biochemistry & Molecular Biology

Therapeutic Efficacy of a VSV-GP-based Human Papilloma Virus Vaccine in a Murine Cancer Model

Lydia Riepler, Laura-Sophie Frommelt, Sarah Wilmschen-Tober, Wilbert Mbuya, Kathrin Held, Andre Prime Volland, Dorothee Von Laer, Christof Geldmacher, Janine Kimpel

Summary: HPV infections are strongly associated with cervical, anogenital, and oropharyngeal cancers. In this study, a live attenuated cancer vaccine based on the VSV-GP virus was generated, which expressed higher amounts of HPV antigens at an earlier position in the genome. This vaccine demonstrated increased immunogenicity and anti-tumoral efficacy in mouse tumor models.

JOURNAL OF MOLECULAR BIOLOGY (2023)

Article Immunology

Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination

Teresa Harthaller, Barbara Falkensammer, David Bante, Maria Huber, Melanie Schmitt, Habib Benainouna, Annika Roessler, Verena Fleischer, Dorothee von Laer, Janine Kimpel, Reinhard Wuerzner, Wegene Borena

Summary: In this study, it was found that antibodies induced by vaccination or infection against SARS-CoV-2 have reduced recognition of the Omicron variant compared to the wild-type virus. However, the remaining antibodies still have non-inferior avidity to the Omicron variant, suggesting functional immunity is retained. Vaccinated individuals have higher antibody levels and greater cross-binding capacity, indicating the advantage of repeated exposure in generating robust immunity.

FRONTIERS IN IMMUNOLOGY (2023)

No Data Available